Cure My Disease

Don't miss your cure!

 Log in / Sign up

A multicenter, randomized, Active-Controlled, Open-Label phase IIb study evaluating safety and tolerability of switching to zovaglutide injection after titration to 2.4 mg semaglutide injection (Wegovy®) in adults with obesity (HORIZON-SWITCH-SZ)

NCT ID NCT07812597

NEW Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 10, 2026

Summary

The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects aged≥18years and≤75 years at the time of signing the Informed Consent Form (ICF). * At screening, Body Mass Index (BMI)≥28kg/m² * Weight change due to diet and exercise alone within 3 months prior to screening did not exceed 5%. Exclusion Criteria: * Previously diagnosed obesity caused by monogenic mutations, other diseases, or medications. * Previous diagnosis of diabetes; or HbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L at screening. * Used of medicines or treatments that affect weight within 3 months prior to screening. * History of acute or chronic pancreatitis, or pancreatic injury. * History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history. * History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history. * Patient Health Questionnaire-9 (PHQ-9) scale score is ≥ 15 at screening * Screening Columbia-Suicide Severity Rating Scale(C-SSRS) questionnaire suicide ideation response of "Category 4 or 5," or any "yes" response to suicidal behavior questions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100050, China

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250000, China

  • Handan First Hospital

    Handan, Hebei, 056002, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, 150001, China

  • Hebei Petro China Cental Hospital

    Langfang, Hebei, 065000, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, 516008, China

  • Jilin Province FAW General Hospital

    Changchun, Jilin, 130011, China

  • Jincheng General Hospital

    Jincheng, Shanxi, 48006, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • The 2nd People's Hospital of Chengdu

    Chengdu, Sichuan, 610021, China

  • The Fifth People's Hospital of Shenyang

    Shenyang, Liaoning, 110023, China

  • The First Affiliated of Nanyang Medical College

    Nanyang, Henan, 473000, China

  • The First People's Hospital of Changde

    Changde, Hunan, 415003, China

  • Yichang Central People's Hospital (Xiling Campus)

    Yichang, Hubei, 443000, China

  • Zibo Central Hospital

    Zibo, Shandong, 255036, China

  • Zibo Municipal Hospital

    Zibo, Shandong, 255400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.